Oakworth Capital’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
Oakworth Capital's PBE Position: Q3 2026 in Review
Oakworth Capital held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2026 at 611 shares worth $59.4K. The position accounts for ﹤0.01% of the portfolio, ranked #437.
Oakworth Capital first reported a position in PBE in Q3 2020 and has held it in 25 quarters since. 122 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- Oakworth Capital held 611 shares of Invesco Biotechnology & Genome ETF worth $59.4K as of Q3 2026.
- Oakworth Capital left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2026.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of Oakworth Capital's portfolio in Q3 2026, its #437 holding.
- Oakworth Capital first reported a position in Invesco Biotechnology & Genome ETF in Q3 2020 and has held it in 25 quarters since.
- 122 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on Oakworth Capital's 13F filing for Q3 2026, filed 26 Oct 2026.